EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

Journal of Hepatology

Volumn 60, Issue 2, 2014, Pages 392-420

  Mutimer, David ^b   Aghemo, Alessio ^b   Diepolder, Helmut ^b   Negro, Francesco ^b   Robaeys, Geert ^b   Ryder, Stephen ^b   Zoulim, Fabien ^b   Peck, Markus ^b   Craxi, Antonio ^b   Fried, Michael ^b   Zeuzem, Stefan ^b  

^a EASL Office   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BOCEPREVIR; ELTROMBOPAG; GRANULOCYTE COLONY STIMULATING FACTOR; PEGINTERFERON ALPHA; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; ROMIPLOSTIM; TELAPREVIR; VIRUS RNA;

ACUTE HEPATITIS; ALCOHOL CONSUMPTION; ALGORITHM; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; COMORBIDITY; DEPRESSION; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; GENOTYPE; HEALTH CARE QUALITY; HEMODIALYSIS PATIENT; HEMOGLOBINOPATHY; HEPATITIS C; HEPATITIS C VIRUS; HISTORY OF MEDICINE; HUMAN; IMMUNOASSAY; IMMUNOCOMPROMISED PATIENT; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MEDICATION COMPLIANCE; METABOLIC SYNDROME X; METHODOLOGY; MIXED INFECTION; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT INFECTION; REINFECTION; RELAPSE; RETREATMENT; TREATMENT INDICATION; TREATMENT RESPONSE; VIRUS GENE; WEIGHT REDUCTION;

ADVERSE EVENT; AE; ALANINE AMINOTRANSFERASE; ALT; BMI; BOC; BOCEPREVIR; BODY MASS INDEX; BT; CLINICAL PRACTICE GUIDELINES; CPGS; CYP3A4; CYTOCHROME P450 3A4; DAA; DELAYED VIROLOGICAL RESPONSE; DIRECT-ACTING ANTIVIRAL; DVR; EARLY VIROLOGICAL RESPONSE; EIA; ENZYME IMMUNOASSAYS; EPO; ERVR; ERYTHROPOIETIN; EVR; EXTENDED RAPID VIROLOGICAL RESPONSE; G-CSF; GRADE; GRADING OF RECOMMENDATIONS ASSESSMENT, DEVELOPMENT AND EVALUATION; GRANULOCYTE COLONY STIMULATING FACTOR; HBV; HCC; HCV; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATOCELLULAR CARCINOMA; IDU; IFN; INTERFERON; INTERNATIONAL UNITS; INTRAVENOUS/INJECTING DRUG USE; IU; LIVER STIFFNESS MEASUREMENT; LIVER TRANSPLANT; LSM; LT; OPIATE/OPIOID SUBSTITUTION TREATMENT/THERAPY; OST; PEGIFN/RBV; PEGYLATED INTERFERON-Α AND RIBAVIRIN; PEOPLE WHO INJECT DRUGS; PI; PROTEASE INHIBITOR; PWID; RAPID VIROLOGICAL RESPONSE; RVR; SCAR; SEVERE CUTANEOUS ADVERSE REACTION; SUSTAINED VIROLOGICAL RESPONSE; SVR; TELAPREVIR; THYROID STIMULATING HORMONE; TSH; TVR; VIRAL BREAKTHROUGH;

ANTIVIRAL AGENTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; OLIGOPEPTIDES; PROLINE; RIBAVIRIN;

EID: 84892529894     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.11.003     Document Type: Article

References (241)

1. EASL Clinical Practice Guidelines Management of hepatitis C virus infection J Hepatol 55 2011 245 264
2. D. Lavanchy Evolving epidemiology of hepatitis C virus Clin Microbiol Infect 17 2011 107 115
3. C. Hepatitis Wkly Epidemiol Rec 72 1997 65 69
4. M. Cornberg, H.A. Razavi, A. Alberti, E. Bernasconi, M. Buti, and C. Cooper et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel Liver Int 31 2011 30 60
5. Blachier M, Leleu H, Peck-Radosavljevic M, Valla D-C, Roudot-Thoraval F. The burden of liver disease in Europe, a review of available epidemiological data. Geneva: European Association for the Study of the, Liver; 2013. www.easl.eu.
6. Rantala M, van de Laar M. Surveillance and epidemiology of hepatitis B and C in Europe - a review. Eur Surveill 2008;13(21): < http://www. eurosurveillance.org/ViewArticle.aspx?ArticleId=18880 >.
7. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C Virus into 7 genotypes and 67 Subtypes: updated criteria and assignment web resource. Hepatology 2013. http://dx.doi.org/10.1002/hep.26744 [Epub ahead of print, PubMed PMID: 24115039.].
8. N. Antaki, A. Craxi, S. Kamal, R. Moucari, S. Van der Merwe, and S. Haffar et al. The neglected hepatitis C virus genotypes 4, 5, and 6: an international consensus report Liver Int 30 2010 342 355
9. D. Murphy, J. Chamberland, R. Dandavino, and E. Sablon A new genotype of hepatitis C virus originating from central Africa Hepatology 46 2007 623A
10. N.K. Martin, P. Vickerman, G.R. Foster, S.J. Hutchinson, D.J. Goldberg, and M. Hickman Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility J Hepatol 54 2011 1137 1144
11. T.J. van de Laar, G.V. Matthews, M. Prins, and M. Danta Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection AIDS 24 2010 1799 1812
12. J.I. Esteban, S. Sauleda, and J. Quer The changing epidemiology of hepatitis C virus infection in Europe J Hepatol 48 2008 148 162
13. H.H. Thein, Q. Yi, G.J. Dore, and M.D. Krahn Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression Hepatology 48 2008 418 431
14. A. John-Baptiste, M. Krahn, J. Heathcote, A. Laporte, and G. Tomlinson The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression J Hepatol 53 2010 245 251
15. J.D. Yang, and L.R. Roberts Hepatocellular carcinoma: a global view Nat Rev Gastroenterol Hepatol 7 2010 448 458
16. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. Stockholm: European Centre for Disease Prevention and Control; 2010.
17. S.A. McDonald, S.J. Hutchinson, S.M. Bird, P.R. Mills, J. Dillon, and M. Bloor et al. A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland Stat Methods Med Res 18 2009 271 283
18. J. Grebely, and G.J. Dore What is killing people with hepatitis C virus infection? Semin Liver Dis 31 2011 331 339
19. L.B. Seeff The history of the "natural history" of hepatitis C (1968-2009) Liver Int 29 2009 89 99
20. A. Mallat, C. Hezode, and S. Lotersztajn Environmental factors as disease accelerators during chronic hepatitis C J Hepatol 48 2008 657 665
21. L. Brunet, E.E. Moodie, K. Rollet, C. Cooper, S. Walmsley, and M. Potter et al. Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis Clin Infect Dis 57 2013 663 670
22. C.E. Costentin, F. Roudot-Thoraval, E.S. Zafrani, F. Medkour, J.M. Pawlotsky, and A. Mallat et al. Association of caffeine intake and histological features of chronic hepatitis C J Hepatol 54 2011 1123 1129
23. A.A. Modi, J.J. Feld, Y. Park, D.E. Kleiner, J.E. Everhart, and T.J. Liang et al. Increased caffeine consumption is associated with reduced hepatic fibrosis Hepatology 51 2010 201 209
24. S. Ohfuji, W. Fukushima, T. Tanaka, D. Habu, A. Tamori, and H. Sakaguchi et al. Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: a case-control study Hepatol Res 36 2006 201 208
25. M.P. Manns, and T. von Hahn Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov 12 2013 595 610
26. J. Andrews, G. Guyatt, A.D. Oxman, P. Alderson, P. Dahm, and Y. Falck-Ytter et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations J Clin Epidemiol 66 2013 719 725
27. S. Chevaliez, and J.M. Pawlotsky Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes Best Pract Res Clin Gastroenterol 22 2008 1031 1048
28. S. Kamili, J. Drobeniuc, A.C. Araujo, and T.M. Hayden Laboratory diagnostics for hepatitis C virus infection Clin Infect Dis 55 2012 S43 S48
29. M.G. Swain, M.Y. Lai, M.L. Shiffman, W.G. Cooksley, S. Zeuzem, and D.T. Dieterich et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin Gastroenterology 139 2010 1593 1601
30. M. Martinot-Peignoux, C. Stern, S. Maylin, M.P. Ripault, N. Boyer, and L. Leclere et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin Hepatology 51 2010 1122 1126
31. L. Castera, J. Vergniol, J. Foucher, B. Le Bail, E. Chanteloup, and M. Haaser et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C Gastroenterology 128 2005 343 350
32. L. Castera, G. Sebastiani, B. Le Bail, V. de Ledinghen, P. Couzigou, and A. Alberti Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C J Hepatol 52 2010 191 198
33. S. Chevaliez, M. Bouvier-Alias, R. Brillet, and J.M. Pawlotsky Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice PLoS One 4 2009 e8209
34. A.J. Thompson, A.J. Muir, M.S. Sulkowski, D. Ge, J. Fellay, and K.V. Shianna et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus Gastroenterology 139 2010 e118
35. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, and T.J. Urban et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
36. C. Hezode, H. Fontaine, C. Dorival, D. Larrey, F. Zoulim, and V. Canva et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890 J Hepatol 59 2013 434 441
37. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
38. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
39. K.E. Sherman, S.L. Flamm, N.H. Afdhal, D.R. Nelson, M.S. Sulkowski, and G.T. Everson et al. Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 2011 1014 1024
40. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
41. S.J. Hadziyannis, H. Sette Jr., T.R. Morgan, V. Balan, M. Diago, and P. Marcellin et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
42. M.P. Manns, H. Wedemeyer, and M. Cornberg Treating viral hepatitis C: efficacy, side effects, and complications Gut 55 2006 1350 1359
43. J.G. McHutchison, E.J. Lawitz, M.L. Shiffman, A.J. Muir, G.W. Galler, and J. McCone et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
44. F. Poordad, J.P. Bronowicki, S.C. Gordon, S. Zeuzem, I.M. Jacobson, and M.S. Sulkowski et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir Gastroenterology 143 2012 e601 e605
45. Buti M, Agarwal K, Horsmans YJ, Sievert W, Janczewska E, Zeuzem S, et al. OPTIMIZE trial: non-inferiority of twice-daily telaprevir vs. administration every 8 h in treatment-naive, genotype 1 HCV infected patients. In: 63rd annual meeting of the American Association for the Study of Liver Diseases, Boston, MA, November 9-13; 2012 [abstract LB8].
46. P. Marcellin, X. Forns, T. Goeser, P. Ferenci, F. Nevens, and G. Carosi et al. Telaprevir is effective given every 8 or 12 h with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C Gastroenterology 140 2011 459 468 [quiz e414]
47. M. Manns, S. Zeuzem, A. Sood, Y. Lurie, M. Cornberg, and H. Klinker et al. Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C J Hepatol 55 2011 554 563
48. P. Marcellin, H. Cheinquer, M. Curescu, G.M. Dusheiko, P. Ferenci, and A. Horban et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials Hepatology 56 2012 2039 2050
49. S. De Nicola, A. Aghemo, M.G. Rumi, E. Galmozzi, L. Valenti, and R. Soffredini et al. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4 Hepatology 55 2012 336 342
50. J. Vermehren, A. Kau, B.C. Gartner, R. Gobel, S. Zeuzem, and C. Sarrazin Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification J Clin Microbiol 46 2008 3880 3891
51. S. Chevaliez, M. Bouvier-Alias, R. Brillet, and J.M. Pawlotsky Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method Hepatology 46 2007 22 31
52. C. Sarrazin, M.L. Shiffman, S.J. Hadziyannis, A. Lin, G. Colucci, and H. Ishida et al. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy J Hepatol 52 2010 832 838
53. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
54. M. Diago, M.L. Shiffman, J.P. Bronowicki, S. Zeuzem, M. Rodriguez-Torres, and S.C. Pappas et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin Hepatology 51 2010 1897 1903
55. M.L. Shiffman, F. Suter, B.R. Bacon, D. Nelson, H. Harley, and R. Sola et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 N Engl J Med 357 2007 124 134
56. D.M. Jensen, T.R. Morgan, P. Marcellin, P.J. Pockros, K.R. Reddy, and S.J. Hadziyannis et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy Hepatology 43 2006 954 960
57. P. Ferenci, H. Laferl, T.M. Scherzer, M. Gschwantler, A. Maieron, and H. Brunner et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response Gastroenterology 135 2008 451 458
58. T. Berg, C. Sarrazin, E. Herrmann, H. Hinrichsen, T. Gerlach, and R. Zachoval et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy Hepatology 37 2003 600 609
59. S. Zeuzem, M. Buti, P. Ferenci, J. Sperl, Y. Horsmans, and J. Cianciara et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia J Hepatol 44 2006 97 103
60. G.L. Davis, J.B. Wong, J.G. McHutchison, M.P. Manns, J. Harvey, and J. Albrecht Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 2003 645 652
61. A. Mangia, N. Minerva, D. Bacca, R. Cozzolongo, G.L. Ricci, and V. Carretta et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial Hepatology 47 2008 43 50
62. C. Moreno, P. Deltenre, J.M. Pawlotsky, J. Henrion, M. Adler, and P. Mathurin Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis J Hepatol 52 2010 25 31
63. T. Berg, M. von Wagner, S. Nasser, C. Sarrazin, T. Heintges, and T. Gerlach et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 vs. 72 weeks of peginterferon-alfa-2a plus ribavirin Gastroenterology 130 2006 1086 1097
64. B.L. Pearlman, C. Ehleben, and S. Saifee Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders Hepatology 46 2007 1688 1694
65. J.M. Sanchez-Tapias, M. Diago, P. Escartin, J. Enriquez, M. Romero-Gomez, and R. Barcena et al. Peginterferon-alfa2a plus ribavirin for 48 vs. 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment Gastroenterology 131 2006 451 460
66. P. Ferenci, H. Laferl, T.M. Scherzer, A. Maieron, H. Hofer, and R. Stauber et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response Gastroenterology 138 2010 503 512 [512 e501]
67. M. Buti, Y. Lurie, N.G. Zakharova, N.P. Blokhina, A. Horban, and G. Teuber et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response Hepatology 52 2010 1201 1207
68. H. Farnik, C.M. Lange, C. Sarrazin, B. Kronenberger, S. Zeuzem, and E. Herrmann Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection Clin Gastroenterol Hepatol 8 2010 884 890
69. O. Dalgard, K. Bjoro, H. Ring-Larsen, E. Bjornsson, M. Holberg-Petersen, and E. Skovlund et al. Pegylated interferon alfa and ribavirin for 14 vs. 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response Hepatology 47 2008 35 42
70. A. Mangia, R. Santoro, N. Minerva, G.L. Ricci, V. Carretta, and M. Persico et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3 N Engl J Med 352 2005 2609 2617
71. M. von Wagner, M. Huber, T. Berg, H. Hinrichsen, J. Rasenack, and T. Heintges et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C Gastroenterology 129 2005 522 527
72. M.L. Yu, C.Y. Dai, J.F. Huang, N.J. Hou, L.P. Lee, and M.Y. Hsieh et al. A randomised study of peginterferon and ribavirin for 16 vs. 24 weeks in patients with genotype 2 chronic hepatitis C Gut 56 2007 553 559
73. A. Kau, J. Vermehren, and C. Sarrazin Treatment predictors of a sustained virologic response in hepatitis B and C J Hepatol 49 2008 634 651
74. M. Romero-Gomez, C.M. Fernandez-Rodriguez, R.J. Andrade, M. Diago, S. Alonso, and R. Planas et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C J Hepatol 48 2008 721 727
75. S. Zeuzem, R. Hultcrantz, M. Bourliere, T. Goeser, P. Marcellin, and J. Sanchez-Tapias et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3 J Hepatol 40 2004 993 999
76. T. Berg, M.L. Shiffman, S. Zeuzem, C.P. Berg, C. de Figueiredo-Mendes, and G.J. Dore et al. 48 Weeks of peginterferon alfa-2a/ribavirin improves SVR24 and decreases relapse across HCV genotype 2/3 patient subgroups not achieving a rapid virological response: N-CORE study J Hepatol 58 2013 S323
77. M.W. Fried Side effects of therapy of hepatitis C and their management Hepatology 36 2002 S237 S244
78. A. Soza, J.E. Everhart, M.G. Ghany, E. Doo, T. Heller, and K. Promrat et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C Hepatology 36 2002 1273 1279
79. M.L. Shiffman, J. Salvatore, S. Hubbard, A. Price, R.K. Sterling, and R.T. Stravitz et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha Hepatology 46 2007 371 379
80. N.H. Afdhal, D.T. Dieterich, P.J. Pockros, E.R. Schiff, M.L. Shiffman, and M.S. Sulkowski et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study Gastroenterology 126 2004 1302 1311
81. P.J. Pockros, M.L. Shiffman, E.R. Schiff, M.S. Sulkowski, Z. Younossi, and D.T. Dieterich et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy Hepatology 40 2004 1450 1458
82. M.S. Sulkowski, F. Poordad, M.P. Manns, J.P. Bronowicki, K. Rajender Reddy, and S.A. Harrison et al. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial Hepatology 57 2013 974 984
83. J.J. Weiss, N. Brau, A. Stivala, T. Swan, and D. Fishbein Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research Aliment Pharmacol Ther 30 2009 14 27
84. J. Grebely, G.V. Matthews, M. Hellard, D. Shaw, I. van Beek, and K. Petoumenos et al. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users J Hepatol 55 2011 76 85
85. P. Marcellin, M. Chousterman, T. Fontanges, D. Ouzan, M. Rotily, and M. Varastet et al. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study Liver Int 31 2011 516 524
86. S.R. Smith, A.S. Wahed, S.S. Kelley, H.S. Conjeevaram, P.R. Robuck, and M.W. Fried Assessing the validity of self-reported medication adherence in hepatitis C treatment Ann Pharmacother 41 2007 1116 1123
87. D.M. Evon, K. Simpson, S. Kixmiller, J. Galanko, K. Dougherty, and C. Golin et al. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment Am J Gastroenterol 106 2011 1777 1786
88. J. Grebely, E. Knight, K.A. Genoway, M. Viljoen, M. Khara, and D. Elliott et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support Eur J Gastroenterol Hepatol 22 2010 270 277
89. S. Arora, K. Thornton, G. Murata, P. Deming, S. Kalishman, and D. Dion et al. Outcomes of treatment for hepatitis C virus infection by primary care providers N Engl J Med 364 2011 2199 2207
90. D. Larrey, A. Salse, D. Ribard, O. Boutet, V. Hyrailles-Blanc, and B. Niang et al. Education by a nurse increases response of patients with chronic hepatitis C to therapy with peginterferon-alpha2a and ribavirin Clin Gastroenterol Hepatol 9 2011 781 785
91. C. Schmidt, B. Schulte, D. Gansefort, J. Goelz, G. Gerken, and N. Scherbaum et al. Optimizing HCV therapy: the impact of psychoeducation on retention and SVR in opiate substituted patients Hepatology 54 2011 821A 822A
92. C.E. Lindenburg, F.A. Lambers, A.T. Urbanus, J. Schinkel, P.L. Jansen, and A. Krol et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project Eur J Gastroenterol Hepatol 23 2011 23 31
93. M. Waizmann, and G. Ackermann High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin J Subst Abuse Treat 38 2010 338 345
94. J. Grebely, J.D. Raffa, C. Meagher, F. Duncan, K.A. Genoway, and M. Khara et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users J Gastroenterol Hepatol 22 2007 1519 1525
95. H.L. Bonkovsky, A.D. Tice, R.G. Yapp, H.C. Bodenheimer Jr., A. Monto, and S.J. Rossi et al. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration Am J Gastroenterol 103 2008 2757 2765
96. D.L. Sylvestre, and J.E. Zweben Integrating HCV services for drug users: a model to improve engagement and outcomes Int J Drug Policy 18 2007 406 410
97. J. Norman, N.M. Walsh, J. Mugavin, M.A. Stoove, J. Kelsall, and K. Austin et al. The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users Harm Reduct J 5 2008 8
98. J.L. Rodis, and P. Kibbe Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy Gastroenterol Nurs 33 2010 368 373
99. S.M. Alavian, and S.H. Aalaei-Andabili Education by a nurse increases the adherence to therapy in chronic hepatitis C patients Clin Gastroenterol Hepatol 10 2012 203 [author reply 203]
100. J.J. Weiss, M.C. Alcorn, J.G. Rabkin, and D.T. Dieterich The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice J Hepatol 56 2012 503 504
101. B.L. Bressler, M. Guindi, G. Tomlinson, and J. Heathcote High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C Hepatology 38 2003 639 644
102. B.S. Anand, S. Currie, E. Dieperink, E.J. Bini, H. Shen, and S.B. Ho et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study Gastroenterology 130 2006 1607 1616
103. C. Le Lan, A. Guillygomarc'h, H. Danielou, G. Le Dreau, F. Laine, and C. Vedeilhie et al. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse J Hepatol 56 2012 334 340
104. P. Bruggmann, M. Dampz, T. Gerlach, L. Kravecz, and L. Falcato Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study Drug Alcohol Depend 110 2010 167 171
105. L. Siu, J. Foont, and J.R. Wands Hepatitis C virus and alcohol Semin Liver Dis 29 2009 188 199
106. L. Serfaty, X. Forns, T. Goeser, P. Ferenci, F. Nevens, and G. Carosi et al. Insulin resistance and response to telaprevir plus peginterferon alpha and ribavirin in treatment-naive patients infected with HCV genotype 1 Gut 61 2012 1473 1480
107. S.A. Harrison, F.M. Hamzeh, J. Han, P.K. Pandya, M.Y. Sheikh, and J.M. Vierling Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin Hepatology 56 2012 464 473
108. T. Thevenot, J.F. Cadranel, V. Di Martino, A. Pariente, X. Causse, and C. Renou et al. A national French survey on the use of growth factors as adjuvant treatment of chronic hepatitis C Hepatology 45 2007 377 383
109. F. Stickel, B. Helbling, M. Heim, A. Geier, C. Hirschi, and B. Terziroli et al. Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C J Viral Hepat 19 2012 77 87
110. S.M. Alavian, S.V. Tabatabaei, and B. Behnava Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis J Viral Hepat 19 2012 88 93
111. F. Poordad, E.J. Lawitz, K.R. Reddy, N.H. Afdhal, C. Hézode, and S. Zeuzem et al. A randomized trial comparing ribavirin dose reduction vs. erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin J Hepatol 56 2012 S559
112. P. Tandon, K. Doucette, K. Fassbender, B. Vandermeer, T. Durec, and D.M. Dryden Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation J Viral Hepat 18 2011 e381 e393
113. J.G. McHutchison, G. Dusheiko, M.L. Shiffman, M. Rodriguez-Torres, S. Sigal, and M. Bourliere et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C N Engl J Med 357 2007 2227 2236
114. S. Homeida, C. Ebdon, P. Batty, B. Jackson, S. Kolade, and C. Bateman et al. New thrombopoietin receptor agonists for platelet disorders Drugs Today (Barc) 48 2012 293 301
115. M. Schaefer, L. Capuron, A. Friebe, C. Diez-Quevedo, G. Robaeys, and S. Neri et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement J Hepatol 57 2012 1379 1390
116. O. Dalgard Follow-up studies of treatment for hepatitis C virus infection among injection drug users Clin Infect Dis 40 2005 S336 S338
117. M. Backmund, K. Meyer, and B.R. Edlin Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users Clin Infect Dis 39 2004 1540 1543
118. S.L. Currie, J.C. Ryan, D. Tracy, T.L. Wright, S. George, and R. McQuaid et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus Drug Alcohol Depend 93 2008 148 154
119. J. Grebely, S.T. Pham, G.V. Matthews, K. Petoumenos, R.A. Bull, and B. Yeung et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection Hepatology 55 2012 1058 1069
120. J. Grebely, E. Knight, T. Ngai, K.A. Genoway, J.D. Raffa, and M. Storms et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users J Gastroenterol Hepatol 25 2010 1281 1284
121. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem et al. Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
122. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts et al. Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
123. S.L. Flamm, E. Lawitz, I. Jacobson, M. Bourliere, C. Hezode, and J.M. Vierling et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection Clin Gastroenterol Hepatol 11 2013 81 [e84; quiz e85]
124. A.G. Singal, M.L. Volk, D. Jensen, A.M. Di Bisceglie, and P.S. Schoenfeld A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus Clin Gastroenterol Hepatol 8 2010 280 288 [288 e281]
125. A.J. van der Meer, B.J. Veldt, J.J. Feld, H. Wedemeyer, J.F. Dufour, and F. Lammert et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
126. M. Schmid, A. Kreil, W. Jessner, M. Homoncik, C. Datz, and A. Gangl et al. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens Gut 54 2005 1014 1020
127. M. Garcia-Retortillo, X. Forns, A. Feliu, E. Moitinho, J. Costa, and M. Navasa et al. Hepatitis C virus kinetics during and immediately after liver transplantation Hepatology 35 2002 680 687
128. X. Forns, M. Garcia-Retortillo, T. Serrano, A. Feliu, F. Suarez, and M. de la Mata et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation J Hepatol 39 2003 389 396
129. J.A. Carrion, E. Martinez-Bauer, G. Crespo, S. Ramirez, S. Perez-del-Pulgar, and J.C. Garcia-Valdecasas et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study J Hepatol 50 2009 719 728
130. G.T. Everson, J. Trotter, L. Forman, M. Kugelmas, A. Halprin, and B. Fey et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy Hepatology 42 2005 255 262
131. M. Prieto, M. Berenguer, J.M. Rayon, J. Cordoba, L. Arguello, and D. Carrasco et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes Hepatology 29 1999 250 256
132. L.M. Forman, J.D. Lewis, J.A. Berlin, H.I. Feldman, and M.R. Lucey The association between hepatitis C infection and survival after orthotopic liver transplantation Gastroenterology 122 2002 889 896
133. M. Berenguer, A. Palau, V. Aguilera, J.M. Rayon, F.S. Juan, and M. Prieto Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation Am J Transplant 8 2008 679 687
134. U.P. Neumann, T. Berg, M. Bahra, D. Seehofer, J.M. Langrehr, and R. Neuhaus et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C J Hepatol 41 2004 830 836
135. A. Blasco, X. Forns, J.A. Carrion, J.C. Garcia-Pagan, R. Gilabert, and A. Rimola et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation Hepatology 43 2006 492 499
136. D. Samuel, T. Bizollon, C. Feray, B. Roche, S.N. Ahmed, and C. Lemonnier et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study Gastroenterology 124 2003 642 650
137. J.A. Carrion, M. Navasa, M. Garcia-Retortillo, J.C. Garcia-Pagan, G. Crespo, and M. Bruguera et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study Gastroenterology 132 2007 1746 1756
138. M. Berenguer Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin J Hepatol 49 2008 274 287
139. N. Selzner, M. Guindi, E.L. Renner, and M. Berenguer Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients J Hepatol 55 2011 207 217
140. V. Garg, R. van Heeswijk, J.E. Lee, K. Alves, P. Nadkarni, and X. Luo Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus Hepatology 54 2011 20 27
141. E. Hulskotte, S. Gupta, F. Xuan, M. van Zutven, E. O'Mara, and H.P. Feng et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers Hepatology 56 2012 1622 1630
142. A. Coilly, B. Roche, D. Botta-Fridlund, V. Leroy, P. Pageaux, and S. Si-Ahmed et al. Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience J Hepatol 56 2012 S21
143. N. Qurishi, C. Kreuzberg, G. Luchters, W. Effenberger, B. Kupfer, and T. Sauerbruch et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection Lancet 362 2003 1708 1713
144. C. Solas, E. Pambrun, M. Winnock, D. Salmon, I. Poizot-Martin, and S. Dominguez et al. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? AIDS 26 2012 2193 2199
145. A. Alberti, N. Clumeck, S. Collins, W. Gerlich, J. Lundgren, and G. Palu et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients J Hepatol 42 2005 615 624
146. M. Opravil, M. Rodriguez-Torres, J. Rockstroh, E. Snoeck, R.T. Chung, and A. Tietz et al. The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCV HIV Clin Trials 13 2012 33 45
147. M. Rodriguez-Torres, J. Slim, L. Bhatti, R. Sterling, M. Sulkowski, and T. Hassanein et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial HIV Clin Trials 13 2012 142 152
148. Dieterich D, Soriano V, Sherman K, Girard P-M, Rockstroh J, Adiwijaya B, et al. Telaprevir in combination with pegylated interferon-alfa-2a+RBV in HCV/HIV-co-infected patients: a 24-week treatment interim analysis. In: 19th conference on retroviruses and opportunistic infections, seattle, WA, March 5-8; 2012 [abstract 46].
149. M. Sulkowski, S. Pol, J. Mallolas, H. Fainboim, C. Cooper, and J. Slim et al. Boceprevir vs. placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial Lancet Infect Dis 13 2013 597 605
150. J.J. Kiser, J.R. Burton, P.L. Anderson, and G.T. Everson Review and management of drug interactions with boceprevir and telaprevir Hepatology 55 2012 1620 1628
151. European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference AIDS 25 2011 399 409
152. A. Potthoff, H. Wedemeyer, W.O. Boecher, T. Berg, S. Zeuzem, and J. Arnold et al. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection J Hepatol 49 2008 688 694
153. A. Potthoff, T. Berg, and H. Wedemeyer Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin Scand J Gastroenterol 44 2009 1487 1490
154. F. Fabrizi, G. Dulai, V. Dixit, S. Bunnapradist, and P. Martin Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients Aliment Pharmacol Ther 18 2003 1071 1081
155. C.H. Liu, C.C. Liang, J.W. Lin, S.I. Chen, H.B. Tsai, and C.S. Chang et al. Pegylated interferon alpha-2a vs. standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study Gut 57 2008 525 530
156. M. Peck-Radosavljevic, J. Boletis, F. Besisik, M.L. Ferraz, L. Alric, and D. Samuel et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease Clin Gastroenterol Hepatol 9 2011 242 248
157. C.H. Liu, C.C. Liang, C.J. Liu, H.B. Tsai, P.H. Hung, and S.J. Hsu et al. Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy Gut 58 2009 314 316
158. M. Treitel, T. Marbury, R.A. Preston, I. Triantafyllou, W. Feely, and E. O'Mara et al. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function Clin Pharmacokinet 51 2012 619 628
159. R. van Heeswijk, A. Vandevoorde, G. Boogaerts, E. De Paepe, R. van Solingen-Ristea, and V. Garg et al. The effect of severe renal impairment on the pharmacokinetics of the investigational HCV protease inhibitor telaprevir J Hepatol 54 2011 S492
160. P.P. Basu, R. Siriki, N.J. Shah, S. Farhat, K. Mittimani, and S. Atluri et al. Telaprevir with adjusted dose of ribavirin in naïve CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C (RCT) J Hepatol 58 2013 S30 S31
161. D.R. Scott, J.K. Wong, T.S. Spicer, H. Dent, F.K. Mensah, and S. McDonald et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand Transplantation 90 2010 1165 1171
162. E. Gane, and H. Pilmore Management of chronic viral hepatitis before and after renal transplantation Transplantation 74 2002 427 437
163. L.B. Van Wagner, T. Baker, S.N. Ahya, J.P. Norvell, E. Wang, and J. Levitsky Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation J Hepatol 51 2009 874 880
164. P. Martin, and F. Fabrizi Hepatitis C virus and kidney disease J Hepatol 49 2008 613 624
165. J.B. Orens, M. Estenne, S. Arcasoy, J.V. Conte, P. Corris, and J.J. Egan et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation J Heart Lung Transplant 25 2006 745 755
166. J. Grebely, J.D. Raffa, C. Lai, T. Kerr, B. Fischer, and M. Krajden et al. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents J Viral Hepat 18 2011 32 41
167. S. Darke, S. Kaye, and J. Duflou Comparative cardiac pathology among deaths due to cocaine toxicity, opioid toxicity and non-drug-related causes Addiction 101 2006 1771 1777
168. C.W. Shepard, L. Finelli, and M.J. Alter Global epidemiology of hepatitis C virus infection Lancet Infect Dis 5 2005 558 567
169. H. Hagan, E.R. Pouget, D.C. Des Jarlais, and C. Lelutiu-Weinberger Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place Am J Epidemiol 168 2008 1099 1109
170. P.K. Nelson, B.M. Mathers, B. Cowie, H. Hagan, D. Des Jarlais, and D. Horyniak et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews Lancet 378 2011 571 583
171. O.G. Pybus, A. Cochrane, E.C. Holmes, and P. Simmonds The hepatitis C virus epidemic among injecting drug users Infect Genet Evol 5 2005 131 139
172. L. van Asten, I. Verhaest, S. Lamzira, I. Hernandez-Aguado, R. Zangerle, and F. Boufassa et al. Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis J Infect Dis 189 2004 292 302
173. J. de Bruijne, J. Schinkel, M. Prins, S.M. Koekkoek, S.J. Aronson, and M.W. van Ballegooijen et al. Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles J Clin Microbiol 47 2009 3832 3838
174. C.H. van den Berg, C. Smit, M. Bakker, R.B. Geskus, B. Berkhout, and S. Jurriaans et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users Eur J Epidemiol 22 2007 183 193
175. S.H. Mehta, J. Astemborski, G.D. Kirk, S.A. Strathdee, K.E. Nelson, and D. Vlahov et al. Changes in blood-borne infection risk among injection drug users J Infect Dis 203 2011 587 594
176. D.M. Patrick, M.W. Tyndall, P.G. Cornelisse, K. Li, C.H. Sherlock, and M.L. Rekart et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection CMAJ 165 2001 889 895
177. L. Maher, J. Li, B. Jalaludin, K.G. Chant, and J.M. Kaldor High hepatitis C incidence in new injecting drug users: a policy failure? Aust N Z J Public Health 31 2007 30 35
178. C. Kim, T. Kerr, K. Li, R. Zhang, M.W. Tyndall, and J.S. Montaner et al. Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting BMC Public Health 9 2009 270
179. E. Roy, M. Alary, C. Morissette, P. Leclerc, J.F. Boudreau, and R. Parent et al. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users Int J STD AIDS 18 2007 23 27
180. J. Bruneau, M. Daniel, Y. Kestens, M. Abrahamowicz, and G. Zang Availability of body art facilities and body art piercing do not predict hepatitis C acquisition among injection drug users in Montreal, Canada: results from a cohort study Int J Drug Policy 21 2010 477 484
181. C. Aitken, J. Lewis, J. Hocking, D. Bowden, and M. Hellard Does information about IDUs' injecting networks predict exposure to the hepatitis C virus? Hepat Monthly 9 2009 17 23
182. K.M. Turner, S. Hutchinson, P. Vickerman, V. Hope, N. Craine, and N. Palmateer et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence Addiction 106 2011 1978 1988
183. J. Rehm, U. Frick, C. Hartwig, F. Gutzwiller, P. Gschwend, and A. Uchtenhagen Mortality in heroin-assisted treatment in Switzerland 1994-2000 Drug Alcohol Depend 79 2005 137 143
184. M.J. Kreek, L. Dodes, S. Kane, J. Knobler, and R. Martin Long-term methadone maintenance therapy: effects on liver function Ann Intern Med 77 1972 598 602
185. N.M. Petry, W.K. Bickel, D. Piasecki, L.A. Marsch, and G.J. Badger Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine Am J Addict 9 2000 265 269
186. V. Andreu, A. Mas, M. Bruguera, J.M. Salmeron, V. Moreno, and S. Nogue et al. Ecstasy: a common cause of severe acute hepatotoxicity J Hepatol 29 1998 394 397
187. S.B. Karch, B.G. Stephens, and C.H. Ho Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicologic profiles J Forensic Sci 44 1999 359 368
188. C. Hezode, F. Roudot-Thoraval, S. Nguyen, P. Grenard, B. Julien, and E.S. Zafrani et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C Hepatology 42 2005 63 71
189. C. Hezode, E.S. Zafrani, F. Roudot-Thoraval, C. Costentin, A. Hessami, and M. Bouvier-Alias et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C Gastroenterology 134 2008 432 439
190. G. Ostapowicz, K.J. Watson, S.A. Locarnini, and P.V. Desmond Role of alcohol in the progression of liver disease caused by hepatitis C virus infection Hepatology 27 1998 1730 1735
191. N.K. Martin, P. Vickerman, A. Miners, G.R. Foster, S.J. Hutchinson, and D.J. Goldberg et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations Hepatology 55 2012 49 57
192. G.J. Dore, M. Hellard, G.V. Matthews, J. Grebely, P.S. Haber, and K. Petoumenos et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection Gastroenterology 138 2010 e121 e122
193. G. Alvarez-Uria, J.N. Day, A.J. Nasir, S.K. Russell, and F.J. Vilar Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection Liver Int 29 2009 1051 1055
194. B. Conway, J. Grebely, H. Tossonian, D. Lefebvre, and S. de Vlaming A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective Clin Infect Dis 41 2005 S73 S78
195. J. Grebely, K.A. Genoway, J.D. Raffa, G. Dhadwal, T. Rajan, and G. Showler et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users Drug Alcohol Depend 93 2008 141 147
196. A. Doab, C. Treloar, and G.J. Dore Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia Clin Infect Dis 40 2005 S313 S320
197. J.R. Kramer, F. Kanwal, P. Richardson, T.P. Giordano, L.A. Petersen, and H.B. El-Serag Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study Am J Gastroenterol 106 2011 483 491
198. H.F. Gidding, M.G. Law, J. Amin, G.A. Macdonald, J.J. Sasadeusz, and T.L. Jones et al. Predictors of deferral of treatment for hepatitis C infection in Australian clinics Med J Aust 194 2011 398 402
199. E.J. Bini, N. Brau, S. Currie, H. Shen, B.S. Anand, and K.Q. Hu et al. Prospective multicenter study of eligibility for antiviral therapy among 4084 U.S. veterans with chronic hepatitis C virus infection Am J Gastroenterol 100 2005 1772 1779
200. F. Kanwal, T. Hoang, B.M. Spiegel, S. Eisen, J.A. Dominitz, and A. Gifford et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient vs. nonpatient factors Hepatology 46 2007 1741 1749
201. G. Robaeys, H. Van Vlierberghe, C. Mathei, M. Van Ranst, L. Bruckers, and F. Buntinx Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes Eur J Gastroenterol Hepatol 18 2006 159 166
202. M. Hellard, R. Sacks-Davis, and J. Gold Hepatitis C treatment for injection drug users: a review of the available evidence Clin Infect Dis 49 2009 561 573
203. V. Papadopoulos, A. Gogou, T. Mylopoulou, and K. Mimidis Should active injecting drug users receive treatment for chronic hepatitis C? Arq Gastroenterol 47 2010 238 241
204. S. Manolakopoulos, M.J. Deutsch, O. Anagnostou, S. Karatapanis, E. Tiniakou, and G.V. Papatheodoridis et al. Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C Liver Int 30 2010 1454 1460
205. P. Bruggmann, L. Falcato, S. Dober, B. Helbling, O. Keiser, and F. Negro et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients J Viral Hepat 15 2008 747 752
206. J.J. Sasadeusz, G. Dore, I. Kronborg, D. Barton, M. Yoshihara, and M. Weltman Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy Addiction 106 2011 977 984
207. D.L. Sylvestre, A.H. Litwin, B.J. Clements, and M.N. Gourevitch The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone J Subst Abuse Treat 29 2005 159 165
208. S. Mauss, F. Berger, J. Goelz, B. Jacob, and G. Schmutz A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance Hepatology 40 2004 120 124
209. R. van Heeswijk, A. Vandevoorde, P. Verboven, G. Boogaerts, E. De Paepe, and R. van Solingen-Ristea et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir J Hepatol 54 2011 S491 S492
210. X. Luo, J. Trevejo, R. Van Heeswijk, and V. Garg No significant effect of the HCV protease inhibitor telaprevir on pharmacokinetics and pharmacodynamics of buprenorphine in HCV-negative volunteers Global Antivir J 7 2011 116 117
211. E. Hulskotte, H. Feng, R. Bruce, L. Webster, F. Xuan, and W. Lin et al. Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy J Gastroenterol Hepatol 27 2012 169 170
212. D. Burger, D. Back, P. Buggisch, M. Buti, A. Craxi, and G. Foster et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions J Hepatol 58 2013 792 800
213. Van Heeswijk R, Boogaerts G, De Paepe E, Van Solingen-Ristea R, Garg V, Beumont M. The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir. In: Fifth international workshop on clinical pharmacology of hepatitis therapy, Boston, MA, June 23-24; 2010 [abstract 12].
214. Hulskotte EGJ, Gupta S, Xuan F, van Zutven MGJA, O'Mara E, Galitz L, et al. Coadministration of the HCV protease inhibitor boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers. In: Sixteenth annual meeting of HEP DART, Koloa, Hawaii, December 4-8; 2011 [poster 121].
215. Garg V, Chandorkar G, Smith F, Alves K, van Heeswijk R. The effect of telaprevir on the pharmacokinetics of midazolam and digoxin. In: Sixth International Workshop on Clinical Pharmacology of Hepatitis Therapy, Cambridge, MA, June 22-23; 2011 [abstract PK-12].
216. Luo X, Van Heeswijk R, Alves K, Garg V. The effect of telaprevir on the pharmacokinetics of alprazolam and zolpidem in healthy volunteers. In: Sixth international workshop on clinical pharmacology of hepatitis therapy, cambridge, MA, June 22-23; 2011 [abstract PK-11].
217. H.H. Maurer, C. Sauer, and D.S. Theobald Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine Ther Drug Monit 28 2006 447 453
218. G. Robaeys, J. Grebely, S. Mauss, P. Bruggmann, J. Moussalli, and A. De Gottardi et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs Clin Infect Dis 57 2013 S129 S137
219. S. Mauss, and H. Klinker Drug-Drug interactions in the treatment of HCV among people who inject drugs Clin Infect Dis 57 2013 S125 S128
220. G. Robaeys, F. Nevens, P. Starkel, I. Colle, P. Van Eyken, and L. Bruckers et al. Previous intravenous substance use and outcome of liver transplantation in patients with chronic hepatitis C infection Transplant Proc 41 2009 589 594
221. A. De Gottardi, M.N. Hilleret, P. Gelez, V. La Mura, O. Guillaud, and P. Majno et al. Injection drug use before and after liver transplantation: a retrospective multicenter analysis on incidence and outcome Clin Transplant 24 2010 564 571
222. J.M. Miró, M. Laguno, A. Moreno, and A. Rimola Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)? J Hepatol 44 2006 S140 S145
223. D.N. Ranney, W.B. Acker, S.N. Al-Holou, L. Ehrlichman, D.S. Lee, and S.A. Lewin et al. Marijuana use in potential liver transplant candidates Am J Transplant 9 2009 280 285
224. K. Webb, L. Shepherd, and J. Neuberger Illicit drug use and liver transplantation: is there a problem and what is the solution? Transpl Int 21 2008 923 929
225. T.P. Kanchana, V. Kaul, C. Manzarbeitia, D.J. Reich, K.C. Hails, and S.J. Munoz et al. Liver transplantation for patients on methadone maintenance Liver Transpl 8 2002 778 782
226. M. Koch, and P. Banys Liver transplantation and opioid dependence JAMA 285 2001 1056 1058
227. L.U. Liu, T.D. Schiano, N. Lau, M. O'Rourke, A.D. Min, and S.H. Sigal et al. Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation Am J Transplant 3 2003 1273 1277
228. K.F. Murray, and R.L. Carrithers AASLD practice guidelines: evaluation of the patient for liver transplantation Hepatology 41 2005 1407 1432
229. P. Harmatz, M.M. Jonas, J.L. Kwiatkowski, E.C. Wright, R. Fischer, and E. Vichinsky et al. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia Haematologica 93 2008 1247 1251
230. D.B. Strader, T. Wright, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C Hepatology 39 2004 1147 1171
231. M.U. Mondelli, A. Cerino, and A. Cividini Acute hepatitis C: diagnosis and management J Hepatol 42 2005 S108 S114
232. J.L. Dienstag Reply Gastroenterology 131 2006 332 333
233. S.M. Kamal Acute hepatitis C: a systematic review Am J Gastroenterol 103 2008 1283 1297 [quiz 1298]
234. T. Santantonio, J. Wiegand, and J.T. Gerlach Acute hepatitis C: current status and remaining challenges J Hepatol 49 2008 625 633
235. J. Wiegand, E. Jackel, M. Cornberg, H. Hinrichsen, M. Dietrich, and J. Kroeger et al. Long-term follow-up after successful interferon therapy of acute hepatitis C Hepatology 40 2004 98 107
236. K. Deterding, N. Gruner, P. Buggisch, J. Wiegand, P.R. Galle, and U. Spengler et al. Delayed vs. immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial Lancet Infect Dis 13 2013 497 506
237. J.M. Micallef, J.M. Kaldor, and G.J. Dore Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies J Viral Hepat 13 2006 34 41
238. J.T. Gerlach, H.M. Diepolder, R. Zachoval, N.H. Gruener, M.C. Jung, and A. Ulsenheimer et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance Gastroenterology 125 2003 80 88
239. T. Poynard, C. Regimbeau, R.P. Myers, T. Thevenot, V. Leroy, and P. Mathurin et al. Interferon for acute hepatitis C Cochrane Database Syst Rev 2002 10.1002/14651858CD000369
240. C. Camma, A. Licata, G. Cabibbo, F. Latteri, and A. Craxi Treatment of hepatitis C: critical appraisal of the evidence Expert Opin Pharmacother 6 2005 399 408
241. H. Hofer, T. Watkins-Riedel, O. Janata, E. Penner, H. Holzmann, and P. Steindl-Munda et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load Hepatology 37 2003 60 64